Search results for "DP"

showing 10 items of 10968 documents

Parental food-related behaviors and family meal frequencies: associations in Norwegian dyads of parents and preadolescent children.

2012

Background: Frequent family meals are associated with healthy dietary behaviors and other desirable outcomes in children and adolescents. Therefore, increased knowledge about factors that may increase the occurrence of family meals is warranted. The present study has its focus on the home food environment, and aims to explore potential associations between parent-reported feeding behaviors and child-reported family meal frequencies. Methods: Cross-sectional surveys were performed among 10-12-year-olds and their parents recruited from eighteen schools in southwest Norway. The child questionnaire included measures of family meal frequencies (breakfast, dinner and supper). The parent questionn…

AdultMalemedicine.medical_specialtyPediatricsTime FactorsFamily mealsCross-sectional studyChild WelfareNorwegianSocial EnvironmentEatingSurveys and QuestionnairesEpidemiologymedicineHumansParent-Child RelationsChildMealsBreakfastMealParentingbusiness.industryNorwayPublic healthdigestive oral and skin physiologyPublic Health Environmental and Occupational HealthSocial environmentVDP::Medical disciplines: 700::Health sciences: 800Feeding BehaviorMiddle AgedChild eatinglanguage.human_languageFeeding practicesPeer reviewCross-Sectional StudiesMenu PlanningHome food environmentlanguageFemaleBiostatisticsbusinessDemographyResearch ArticleBMC public health
researchProduct

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.

2021

Summary Background There is no evidence that phlebotomy alone is sufficient to steadily maintain haematocrit on target level in low-risk patients with polycythaemia vera. This study aimed to compare the efficacy and safety of ropeginterferon alfa-2b on top of the standard phlebotomy regimen with phlebotomy alone. Methods In 2017, we launched the Low-PV study, a multicentre, open-label, two-arm, parallel-group, investigator-initiated, phase 2 randomised trial with a group-sequential adaptive design. The study involved 21 haematological centres across Italy. Participants were recruited in a consecutive order. Participants enrolled in the study were patients, aged 18–60 years, with a diagnosis…

AdultMalemedicine.medical_specialtyPolycythaemiaNeutropeniaAdolescentPolicithemia veraInterferon alpha-2Polymorphism Single Nucleotidelaw.inventionPolyethylene Glycols03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled trialPhlebotomylawBone MarrowInternal medicinemedicineClinical endpointData monitoring committeeHumansPolycythemia Verabusiness.industryStandard treatmentInterferon-alphaHematologyPhlebotomyJanus Kinase 2Middle AgedInterim analysismedicine.diseaseRecombinant ProteinsRegimenTreatment Outcome030220 oncology & carcinogenesisQuality of LifeFemalebusiness030215 immunologyThe Lancet. Haematology
researchProduct

An observational study to evaluate the long-term outcomes of treatment with etanercept in patients with plaque-type psoriasis

2015

Background There is an unmet need for long-term, real-life data on the effect of a drug-free interval between treatment cycles in patients with plaque psoriasis being treated with etanercept, which is licensed for intermittent and continuous treatment. Objective The aim of this study was to determine the average duration of the drug-free interval between etanercept treatment cycles in patients with plaque psoriasis. Methods This was a non-interventional, open-label, multicentre, prospective study in patients for whom the decision had already been made to initiate treatment with etanercept during routine practice in German centres. Clinical outcomes were documented over 36 months with study …

AdultMalemedicine.medical_specialtyPopulationDermatologyEtanerceptEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePsoriasis Area and Severity IndexInternal medicinePsoriasisClinical endpointHumansPsoriasisMedicineAdverse effecteducationBody surface areaeducation.field_of_studybusiness.industryDermatology Life Quality IndexMiddle Agedmedicine.diseaseSurgeryInfectious Diseases030220 oncology & carcinogenesisFemalebusinessImmunosuppressive Agentsmedicine.drugJournal of the European Academy of Dermatology and Venereology
researchProduct

Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia

2007

Patients with neutropenia resulting from chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome are at high risk for difficult-to-treat and often fatal invasive fungal infections.In this randomized, multicenter study involving evaluators who were unaware of treatment assignments, we compared the efficacy and safety of posaconazole with those of fluconazole or itraconazole as prophylaxis for patients with prolonged neutropenia. Patients received prophylaxis with each cycle of chemotherapy until recovery from neutropenia and complete remission, until occurrence of an invasive fungal infection, or for up to 12 weeks, whichever came first. We compared the incidence of prove…

AdultMalemedicine.medical_specialtyPosaconazoleAntifungal AgentsNeutropeniaAdolescentItraconazolemedicine.medical_treatmentAntineoplastic AgentsKaplan-Meier EstimateOpportunistic InfectionsNeutropeniaInternal medicineClinical endpointmedicineHumansSingle-Blind MethodFluconazoleAgedAged 80 and overChemotherapyLeukopeniabusiness.industryMyelodysplastic syndromesGeneral MedicineMiddle AgedTriazolesmedicine.diseaseSurgeryLeukemia Myeloid AcuteTreatment OutcomeMycosesMyelodysplastic SyndromesFemaleItraconazolemedicine.symptombusinessFluconazolemedicine.drugNew England Journal of Medicine
researchProduct

Do patients with gastroesophageal reflux disease and somatoform tendencies benefit from antireflux surgery?

2019

Source at http://dx.doi.org/10.3748/wjg.v25.i3.388. BACKGROUND - The clinical presentation of gastroesophageal reflux disease (GERD) shows a large symptom variation also in different intensities among patients. As several studies have shown, there is a large overlap in the symptomatic spectrum between proven GERD and other disorders such as dyspepsia, functional heartburn and/or somatoform disorders. AIM - To prospectively evaluate the GERD patients with and without somatoform disorders before and after laparoscopic antireflux surgery. METHODS - In a tertiary referral center for foregut surgery over a period of 3 years patients with GERD, qualifying for the indication of laparoscopic antire…

AdultMalemedicine.medical_specialtyPsychometricsFundoplicationDiseaseLaparoscopic fundoplicationGastroesophageal reflux disease03 medical and health sciencesYoung Adult0302 clinical medicineQuality of lifeInternal medicineVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Gastroscopic surgery: 781medicineHumansddc:610Prospective StudiesYoung adultAntireflux surgeryLaparoscopyProspective cohort studySomatoform DisordersVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Gasteroenterologisk kirurgi: 781AgedAged 80 and overmedicine.diagnostic_testbusiness.industryGastroenterologyRefluxGeneral MedicineMiddle Agedmedicine.diseasehumanitiesdigestive system diseasesTreatment OutcomeSomatization030220 oncology & carcinogenesisGERDGastroesophageal RefluxQuality of LifeProspective Study030211 gastroenterology & hepatologyFemaleLaparoscopybusinessSomatizationGastroesophageal reflux disease symptomsWorld Journal of Gastroenterology
researchProduct

OASIS-HT: design of a pharmacogenomic dose-finding study.

2005

Experimental evidence and observations in humans strongly support an interactive role of mutated α-adducin, sodium (Na+)/potassium (K+)-adenosine triphosphatase (ATPase) activity and endogenous ouabain in Na+homeostasis and the pathogenesis of hypertension. The Ouabain and Adducin for Specific Intervention on Sodium in HyperTension (OASIS-HT) trial is an early Phase II dose-finding study, which will be conducted across 39 European centers. Following a run-in period of 4 weeks without treatment, eligible patients will be randomized to one of five oral doses of rostafuroxin consisting of 0.05, 0.15, 0.5, 1.5, or 5.0 mg/day. Each dose will be compared to a placebo in a double-blind crossover e…

AdultMalemedicine.medical_specialtyRandomizationTime FactorsSystolic hypertensionMolecular ConformationAdministration OralBlood PressurePharmacologyPlaceboOuabainDrug Administration ScheduleDouble-Blind MethodRisk FactorsInternal medicineGeneticsClinical endpointMedicineHumansAndrostanolsOuabainAntihypertensive AgentsPharmacologyCross-Over StudiesDose-Response Relationship Drugbusiness.industryMiddle Agedmedicine.diseaseCrossover studyBlood pressureEndocrinologyTreatment OutcomeHypertensionMolecular MedicineCalmodulin-Binding ProteinsFemalebusinessHomeostasismedicine.drugPharmacogenomics
researchProduct

Comparison of topical tacrolimus 0.1 % in pectin ointment with clobetasol 0.5% ointment in adults with moderate to severe desquamative gingivitis: A …

2006

BACKGROUND: Desquamative gingivitis (DG) is a clinical condition characterized by red, painful, glazed, and friable gingiva, which might be a manifestation of some autoimmune mucocutaneous diseases. The time from the development of initial signs of DG to diagnosis can vary from months to years. Based on a literature search, no data concerning patients with DG without signs of autoimmune disease were available. OBJECTIVE: The aim of this trial was to compare the efficacy and tolerability of monotherapy with topical tacrolimus 0.1% in pectin ointment versus clobetasol propionate 0.5% ointment in adults affected by DG. METHODS: This randomized, double-blind clinical trial was conducted at the …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaErythemaAdministration TopicalPopulationSeverity of Illness IndexTacrolimuslaw.inventionOintmentsRandomized controlled trialDouble-Blind Methodlawdesquamative gingivitimedicineClinical endpointHumansPharmacology (medical)educationAgedPharmacologyeducation.field_of_studyDose-Response Relationship Drugbusiness.industryMiddle Agedmedicine.diseaseDermatologyGingivitisdesquamative gingivitisTacrolimusSurgeryDesquamative gingivitisTreatment OutcomeTolerabilityclobetasoltopical tacrolimus; clobetasol; desquamative gingivitis; randomized double-blind clinical trialtacrolimus clobetasol desquamative gingivitisPectinsDrug Therapy CombinationFemaleClobetasol propionatemedicine.symptombusinessImmunosuppressive Agentsmedicine.drugFollow-Up Studiestopical tacrolimurandomized double-blind clinical trial
researchProduct

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

2015

The efficacy and safety of nab-paclitaxel versus dacarbazine in patients with metastatic melanoma was evaluated in a phase III randomized, controlled trial.Chemotherapy-naïve patients with stage IV melanoma received nab-paclitaxel 150 mg/m(2) on days 1, 8, and 15 every 4 weeks or dacarbazine 1000 mg/m(2) every 3 weeks. The primary end point was progression-free survival (PFS) by independent radiologic review; the secondary end point was overall survival (OS).A total of 529 patients were randomized to nab-paclitaxel (n = 264) or dacarbazine (n = 265). Baseline characteristics were well balanced. The majority of patients were men (66%), had an Eastern Cooperative Oncology Group status of 0 (7…

AdultMalemedicine.medical_specialtySkin NeoplasmsPaclitaxelDacarbazineGastroenterologyDisease-Free Survivallaw.inventionYoung AdultRandomized controlled triallawInternal medicineAlbuminsmedicineClinical endpointHumansProgression-free survivalAntineoplastic Agents AlkylatingMelanomaAgedAged 80 and overbusiness.industryMelanomaHazard ratioHematologyOriginal ArticlesMiddle Agedmedicine.diseaseChemotherapy regimenConfidence intervalSurgeryDacarbazineOncologyFemalebusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.

2021

Summary Background Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy. Cemiplimab, a PD-1 antibody, is approved for treatment of advanced cutaneous squamous cell carcinoma and has shown clinical activity as monotherapy in first-line non-small-cell lung cancer. Here, we present the primary analysis data of cemiplimab in patients with locally advanced basal cell carcinoma after HHI therapy. Methods We did an open-label, multicentre, single-arm, phase 2 trial across 38 outpatient clinics, primarily at academic medical centres, in Canada, Europe, and the USA. Eligible patients (aged ≥18 years…

AdultMalemedicine.medical_specialtySkin NeoplasmsPyridinesProgrammed Cell Death 1 ReceptorVismodegibAntibodies Monoclonal Humanized030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaClinical endpointOutpatient clinicHumansBasal cell carcinomaAnilidesHedgehog ProteinsLung cancerImmune Checkpoint InhibitorsAgedbusiness.industryStandard treatmentMiddle Agedmedicine.diseaseRegimenOncologyCarcinoma Basal CellDrug Resistance Neoplasm030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalSettore MED/35 - MALATTIE CUTANEE E VENEREEbusinessmedicine.drugThe Lancet. Oncology
researchProduct

Endovascular therapy for vasospasm after aneurysmatic subarachnoid hemorrhage

2016

Balloon angioplasty and/or selective intra-arterial vasodilator therapies are treatment options in patients with vasospasm after subarachnoid hemorrhage (SAH). We analyzed the effect of balloon angioplasty and/or selective intra-arterial vasodilator therapy in our patients.Twenty-six patients (vasodilation group, VDT) were treated with intra-arterial nimodipine. The balloon angioplasty with nimodiopine-group (BAP-N group) comprised 21 patients. The primary endpoint of this study was successful angiographic vessel dilation in vasospastic vessels after balloon angioplasty, together with nimodipine (BAP-N group), compared to intra-arterial vasodilator therapy (VDT group) with nimodipine alone.…

AdultMalemedicine.medical_specialtySubarachnoid hemorrhageVasodilator Agentsmedicine.medical_treatmentCerebral arteriesVasodilationBalloon030218 nuclear medicine & medical imaging03 medical and health sciencesPostoperative Complications0302 clinical medicineInternal medicineAngioplastymedicineClinical endpointHumansVasospasm IntracranialNimodipineAgedRetrospective Studiesbusiness.industryEndovascular ProceduresVasospasmGeneral MedicineCerebral ArteriesMiddle AgedSubarachnoid Hemorrhagemedicine.diseaseTreatment OutcomeInjections Intra-ArterialAnesthesiaCardiologyFemaleNimodipineSurgeryPatient SafetyNeurology (clinical)businessAngioplasty Balloon030217 neurology & neurosurgerymedicine.drugBritish Journal of Neurosurgery
researchProduct